Report an error   


Submitted: 07 August 2014 Modified: 10 March 2015
HERDIN Record #: NCR-JAFES-14080717581783

A Comparison of the Sensitivity and Specificity of Ultrasound Elastography Compared to Liver Ultrasound, ALT, and AST in the Detection of Fatty Liver and Fibrosis in Patients with Metabolic Syndrome and Type 2 Diabetes Mellitus

See More

Methodology. All elastography results from January to December, 2013 were reviewed.  A total of 102 patients met the inclusion/exclusion criteria. The sensitivity and specificity of elastograph, ultrasound, ALT and AST were computed, with fibrosis score as the surrogate gold standard. 


Results. Elastography was found to be more sensitive compared to ultrasound for patients with diabetes and metabolic syndrome who have high and moderate probability of fibrosis (100% vs 82.5%, p-value = 0.0036 and  96% vs 76.4%, p-value = 0.0036, respectively). The elastograph is also more specific compared to ultrasound (86.49% vs 32.43%, p-value = 0.0000) for detecting fatty liver and fibrosis. Only elastography was found to be significantly associated with the surrogate gold standard used in this study.


Conclusion.  Elastograph (fibroscan) is more sensitive and specific than ultrasound in detecting fatty liver in the presence of severe and moderate probability for fibrosis. Ultrasound, ALT and AST showed no correlation with fibrosis score.  


 

This study aims to determine whether ultrasound elastography (fibroscan) is more sensitive and specific in detecting fatty liver and fibrosis as compared to  ultrasound and elevated serum aminotransferase levels in patients with type 2 diabetes mellitus and metabolic syndrome.


 

Publication Type
Journal
Publication Sub Type
Journal Article, Original
Title
Journal of the ASEAN Federation of Endocrine Societies
Frequency
Semi-Annual
Publication Date
May 2014
Volume
29
Issue
1
Page(s)
59-64

Objectives

This study aims to determine whether ultrasound elastography (fibroscan) is more sensitive and specific in detecting fatty liver and fibrosis as compared to  ultrasound and elevated serum aminotransferase levels in patients with type 2 diabetes mellitus and metabolic syndrome.


 

LocationLocation CodeAvailable FormatAvailability
http://www.asean-endocrinejournal.org +632-637-3162 Fulltext External Link (View)
1. "Kelley DE, McKolanis TM, Hegazi RAF, Kuller LH and Kalhan SC. Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance" Am J Physiol Endocrinol Metab 285, E906-E916, 2003
2. "Marchesini G, et al. Nonalcoholic fatty liver disease a feature of the metabolic syndrome" Diabetes 50, 1844-1850, 2001
3. "Wieckowska A and Feldstein AE. Diagnosis of nonalcoholic fatty liver disease: Invasive versus noninvasive" Seminars in Liver Disease 28(4): 386-395, 2008
4. "Garcia-Compean DK, et al. Liver cirrhosis and diabetes: Risk factors, pathophysiology, clinical implications and management" World Journal of Gastroenterology , 42-56, 2009
5. "Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: A longitudinal study of 103 patients with sequential liver biopsies" Journal of Hepatology 42, 132-138, 2005
6. "Myers RP, et al. Noninvasive diagnosis of nonalcoholic fatty liver disease" Annals of Hepatology 81(1): S25-S33, 2009
7. "Adams LA and Angulo P. Recent concepts in non?alcoholic fatty liver disease" Diabetic Medicine 22(9): 1129-1133, 2005
8. "Poynard T, et al. The diagnostic value of biomarkers for the prediction of liver steatosis" Comp Hepatology 4, 10, 2005
9. "Erbey JR, Silberman C, Lydick E. Prevalence of abnormal serum alanine amino transferase level in obese patients and patients with type 2 diabetes" American Journal of Medicine 109(7): 588-590, November 2000
10. "Yin-Yan L, Xue-Mei W, et al. Ultrasonic elastography in clinical quantitative assessment of fatty liver" World Journal of Gastroenterology , 12-25, 2010
11. "Angulo P, et al. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD" Journal of Hepatology 45(4): 846-54, 2007
12. (). Consensus worldwide definition of metabolic syndrome. www.IDF.org. . Retrieved from: http//:www.idf.org/webdata/docs/IDF_Meta_def_final.pdf
13. "Foucher J, et al. Diagnosis of cirrhosis by transient elastography (fibroscan): A prospective study" GUT , 124-156, 2006
14. "Somaye K, et al. Non-alcoholic fatty liver disease and correlation of serum alanine aminotransferase level with histopathologic findings" Hepatitis Monthly 11(6): 452-458, 2011
15. "Paschos P, Paletas K. Non-alcoholic fatty liver disease and metabolic syndrome" Hippokratia 13(1): 9-19, 2009
16. "Prati D, Taioli E, Zanella E. Updated definitions of healthy ranges for serum alanine transferase levels" Ann. Med. Int 137, 1-11, 2002
17. "Smith BW, Adams LA. Nonalcoholic fatty liver disease and diabetes mellitus: Pathogenesis and treatment" Nature Reviews Endocrinology 7(8): 456-465, 2011
18. "Levinthal G and Tavill A. Liver disease and diabetes mellitus" Clinical Diabetes , 498-532, 2010
19. "Oikawa S, Fon Tracer K, Rozman D. Nonalcoholic fatty liver disease: Focus on lipoprotein and lipid deregulation" Journal of Lipids 28(4): 339-350, 2011
20. "Demir M, Lang S, Schlattjan M, Drebber U, Wedemeyer I, et al. NIKEI: A new inexpensive and non-invasive scoring system to exclude advanced fibrosis in patients with NAFLD" PLoS ONE.doi:10.1371/journal.pone.0058360 8(3): e58360, 2013

Copyright © One Window Project 2018. All rights reserved.